{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-26-000009","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.465372+00:00","generated_at":"2026-05-15T18:08:28.392809+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AEON Biopharma appoints John Bencich as CFO, amends inducement plan by 1M shares","bullets":["John Bencich appointed CFO effective March 9, 2026; base salary $450k, bonus target 40%.","Equity grants: 754,717 RSUs (4-year vest) and 235,849 PSUs tied to NYSE American compliance.","Jennifer Sy enters CAO employment agreement with $275k base, 30% bonus target, and severance terms.","Board adds 1,000,000 shares to 2025 Inducement Plan for equity awards without stockholder approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-26-000009","json":"https://secwatch.observer/filing/0001837607-26-000009.json","markdown":"https://secwatch.observer/filing/0001837607-26-000009.md","text":"https://secwatch.observer/filing/0001837607-26-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000009/0001837607-26-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000009/aeon-20260306x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:08:28.392809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}